| Previous Section | Index | Home Page |
Mental Health Institutions (Medical Emergencies)
33. Mrs. Brinton: To ask the Secretary of State for Health if he will include in the code of practice under the Mental Health Acts a requirement for mental health institutions to have procedures for dealing with medical emergencies. [77731]
Mr. Hutton:
The Mental Health Act 1983 code of practice provides guidance on the treatment, care and management of patients, with respect to their mental disorder, who are detained under the Mental Health Act
30 Mar 1999 : Column: 650
1983. The code does not provide detailed guidance on procedures for dealing with medical emergencies in mental health institutions. It is for each mental health trust to ensure that policies and procedures are in place for dealing with medical emergencies involving all psychiatric patients, not just those detained under the Act.
34. Mr. Kirkwood:
To ask the Secretary of State for Health if he will make a statement on his proposed timetable for the implementation of the recommendations of the royal commission on long-term care. [77732]
Mr. Hutton:
There is already action in hand relating to several of the Royal Commission's recommendations. Others will require more detailed consideration over the coming months.
35. Mr. Bercow:
To ask the Secretary of State for Health if he will make a statement on the prescription of beta-interferon for multiple sclerosis sufferers. [77733]
Mr. Hutton:
I refer the hon. Member to the reply given to the hon. Member for Sutton and Cheam (Mr. Burstow) today, Official Report, column 845.
36. Mr. Pike:
To ask the Secretary of State for Health what additional resources his Department has made available for renal unit facilities. [77734]
Mr. Denham:
Funds for specific services or aspects of treatment provided by the national health service are not separately identified either nationally or within individual health authority or NHS trust allocations. The pressures on renal services were identified during the comprehensive spending review process and were taken into account when calculating the final settlement for the NHS. However, it is for individual HAs to decide the resources which should be devoted to the provision of renal services in the context of local priorities and needs. The "National Priorities Guidance 1999/2000-2001/02" makes it clear that this is an area where HAs are expected to secure improvements.
38. Mr. Corbett:
To ask the Secretary of State for Health if he will make a statement on Government policy on the provision of health services to patients with multiple sclerosis. [77736]
Mr. Denham:
The national health service provides health care on the basis of clinical need. This includes the health services which may be required by people with multiple sclerosis ranging from primary care to specialist services.
Guidance on betainterferon was issued to the national health service in November 1995.
Mr. Soley:
To ask the Secretary of State for Health what investment the Government plan to make over the next three years to help children with (a) attention deficit disorder, (b) phobias, (c) depression and (d) other mental health problems. [77708]
30 Mar 1999 : Column: 651
Mr. Hutton:
The Government are making an additional £84 million available over three years from April 1999 to improve provision of appropriate, high-quality care and treatment for children and young people by building up locally based child and adolescent mental health services. These services address a range of child and adolescent mental health problems, including emotional and behavioural disorders such as attention deficit disorder, phobias and depression.
Mr. Tredinnick:
To ask the Secretary of State for Health how many deaths occurred last year from (i) prostate, (ii) breast, (iii) lung and (iv) colon cancer; and what was the amount of Government funding for (a) treatment and (b) research allocated to each of those cancers. [77572]
Mr. Hutton:
The number of deaths in England and Wales in 1997 (the latest data available) for the following cancers are given in the table.
| ICD code | Men | Women | |
|---|---|---|---|
| ICD9 185 | Prostate | 8,523 | -- |
| ICD9 174/5 | Breast | 67 | 11,980 |
| ICD9 162 | Trachea, bronchus and lung | 19,087 | 10,889 |
| ICD9 153 | Colon | 5,125 | 5,323 |
Information about the cost of treatment classified by disease is not routinely collected locally, hence there is no collation of such data centrally. However, approximately 6.3 per cent. of national health service hospital expenditure is on cancer.
The Government fund health and medical research in a number of ways. The Department funds research and development to support its work on policy development and evaluation in health and social care. The Department also manages the national health service research and development levy, which is used to support research and development of relevance to the national health service in hospitals, general practice and other health care settings, and to fund the NHS research and development programme. In addition, the Medical Research Council (MRC), which receives most of its income via grant-in-aid from the Office of Science and Technology in the Department of Trade and Industry, funds medical research as part of the Government's funding of the science and engineering base.
Management of much of the research supported by the NHS research and development levy is devolved, and details of expenditure at project level are not collected routinely by the Department. During 1997-98, the Department invested the following amount on directly commissioned research: £187,000 on lung cancer; £29,000 on prostate cancer; £832,000 on breast cancer and £197,000 on bowel cancer.
During 1997-98, the MRC spent £691,000 on lung cancer; £18,000 on prostate cancer; £3,328,000 on breast cancer and £1,469,000 on bowel cancer. The MRC's figures relate to research specifically into these named cancers, and research which has been classified as being undertaken in one of these sites may well have implications in another and vice versa. As a guide, the MRC spent £13.2 million on cancer in 1994-95.
30 Mar 1999 : Column: 652
Studies in cancer should be viewed in the context of a large body of basic MRC research which underpins, and is of some relevance, to them. This includes the study of molecules and cells (£64.5 million in 1997-98), genetics and health (£52.4 million) and infections and immunity (£60.3 million).
In addition to the MRC's funding of the specified cancers, it is also supporting 10 trials, details of which are listed. These trials are co-ordinated by the MRC cancer trials office (CTO), which supports about 30 trials at any one time. Costs cannot be ascribed to individual studies, but, as a guide, the CTO's budget in 1997-98 was approximately £1 million.
Project details of work directly funded by the Department or supported through the NHS research and development levy can be found on the National Research Register (NRR). This is available in the Library and most medical libraries on CD Rom, and on the Internet: http://www.doh.gov.uk/nrr.htm. The NRR also contains many details of projects/trials funded by the MRC and other funders.
Mr. Paul Marsden:
To ask the Secretary of State for Health what information his Department makes available to the public on the quality and performance of cancer care services; and if he will make a statement. [78222]
Mr. Hutton:
A range of information is available which has a bearing on the quality and performance of cancer care services. Annual statistical bulletins on the breast and cervical screening programmes in England give information on uptake, coverage and detection rates. The
30 Mar 1999 : Column: 653
Office for National Statistics publishes the following information on cancer incidence, cancer survival and mortality:
MRC Trials
Breast cancer:
A randomised trial of epirubicin and cyclophosphamide vs. epirubicin and paclitaxel in metastatic breast cancer
Bowel cancer:
A randomised trial of intravenous versus intrahepatic arteria 5-FU and leucovorin for colorectal liver metastases
A randomised trial comparing 2 durations and 3 systemic chemotherapy regimens in the palliative treatment of advanced colorectal cancer
Lung cancer:
The Big Lung Trial: a randomised trial of cisplatin-based chemotherapy for all patients with non-small cell lung cancer;
A randomised trial of supportive treatment with or without immediate thoracic radiotherapy in the prevention and palliation of symptoms in inoperable NSCLC;
A randomised trial of pre-operative chemotherapy versus radiotherapy in patients with stage IIIA NSCLC;
A randomised trial of ifosfamide, carboplatin and etoposide with mid-cycle vincristine (VICE) vs. standard practice chemotherapy in patients with SCLC and good performance status;
A randomised trial of surgical resection with or without pre-operative chemotherapy in patients with operable NSCLC;
Prostate cancer:
A randomised double-blind placebo-controlled trial of adjuvant oral sodium clodronate in patients commencing or responding to initial hormone therapy for metastatic adenocarcinoma comparing time to symptomatic bone progression;
A randomised trial of high dose therapy in localised cancer of the prostate using conformal radiotherapy techniques.
| Source | |
|---|---|
| Incidence | Cancer Statistics Registrations England and Wales 1992 ONS Series MB1 |
| Cancer survival | ONS Monitor MB1 98/1 Cancer survival in England and Wales: 1981 and 1989 registrations |
| Mortality | Mortality Statistics Cause England and Wales 1997 ONS Series DH2 No.24 |
Waiting list data by specialty are collected and published quarterly in both the "Department of Health NHS Executive Hospital Waiting List Statistics: England" for inpatients and the "Department of Health NHS Executive Waiting Times for First Outpatient Appointments in England: Detailed Statistics" for outpatients. Data are available at specialty level for both health authorities and national health service trusts. Cancer treatment data may be contained within some of the various specialty classifications. Hospital episode statistics, which show the number of finished consultant episodes, are also collected. Copies of all publications are available in the Library.
| Next Section | Index | Home Page |